Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia

Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia Opinion EDITORIAL Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia Roger S. Ho, MD, MS, MPH Since its approval for the treatment of male-pattern androge- in clinical trials. Such was the case with finasteride. The netic alopecia by the United States Food and Drug Adminis- associated reporting bias, along with the lack of power, may tration in 1997, finasteride has continued to be at the center result in many missed associations. Plagued by these biases of many controversies regard- and heterogeneity, even meta-analyses of these clinical trials ing its adverse events. Al- may not provide prescribers a full picture of the drug’s Related article though sexual adverse events adverse events. were included in the original A way to explore the potentially missed adverse events of label of finasteride, little attention was initially paid to the 2002 a drug is through analyzing adverse drug event databases via elimination of the word “all” in the drug monograph regard- a validated pharmacovigilance methodology. The now well- ing sexual adverse events, changing the language from “reso- known risk of a serum sickness–like reaction related to cefa- lution occurred in all men who discontinued therapy” to “reso- clor was identified through http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia

JAMA Dermatology, Volume 157 (1) – Jan 11, 2021

Loading next page...
 
/lp/american-medical-association/ongoing-concerns-regarding-finasteride-for-the-treatment-of-male-AD80QFTijn
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2020.3384
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia Roger S. Ho, MD, MS, MPH Since its approval for the treatment of male-pattern androge- in clinical trials. Such was the case with finasteride. The netic alopecia by the United States Food and Drug Adminis- associated reporting bias, along with the lack of power, may tration in 1997, finasteride has continued to be at the center result in many missed associations. Plagued by these biases of many controversies regard- and heterogeneity, even meta-analyses of these clinical trials ing its adverse events. Al- may not provide prescribers a full picture of the drug’s Related article though sexual adverse events adverse events. were included in the original A way to explore the potentially missed adverse events of label of finasteride, little attention was initially paid to the 2002 a drug is through analyzing adverse drug event databases via elimination of the word “all” in the drug monograph regard- a validated pharmacovigilance methodology. The now well- ing sexual adverse events, changing the language from “reso- known risk of a serum sickness–like reaction related to cefa- lution occurred in all men who discontinued therapy” to “reso- clor was identified through

Journal

JAMA DermatologyAmerican Medical Association

Published: Jan 11, 2021

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month